Gilead, Indian Generic Co. Drop Truvada Infringement Suit

Law360 (October 9, 2018, 4:26 PM EDT) -- Gilead Sciences Inc. has asked a Delaware federal court to dismiss yet another patent infringement case against a drugmaker attempting to sell a generic version of its blockbuster HIV preventative medication Truvada, with hints that a settlement is being hammered out.

Gilead, patent owner Emory University and generic drugmaker Aurobindo Pharma Ltd. asked the court to dismiss the litigation with prejudice, with each side handling its own finances. While the stipulation and proposed order of dismissal filed Friday noted nothing about a settlement, court records showed one was in the works.

Representatives for Gilead and Aurobindo didn't immediately respond to requests for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!